Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. (Q40227841)
Jump to navigation
Jump to search
scientific article published on 12 April 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. |
scientific article published on 12 April 2017 |
Statements
1 reference
Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. (English)
1 reference
Marina G Tarakanovskaya
1 reference
Jigjidsuren Chinburen
1 reference
Purev Batchuluun
1 reference
Chogsom Munkhzaya
1 reference
Genden Purevsuren
1 reference
Dorjiin Dandii
1 reference
Tsogkhuu Hulan
1 reference
Dandii Oyungerel
1 reference
Galyna A Kutsyna
1 reference
Alan A Reid
1 reference
Vika Borisova
1 reference
Allen I Bain
1 reference
Vichai Jirathitikal
1 reference
Aldar S Bourinbaiar
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference